Orexo
Sustainability Report and Carbon Intensity Rankings
Is Orexo doing their part?
Their DitchCarbon score is 48
Orexo has a DitchCarbon Score of 48 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, suggesting there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing environmental sustainability.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Orexo is part of the industrial manufacturing sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which Orexo operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Orexo is situated in Sweden, a country with a very low carbon intensity rating, indicating a cleaner energy grid. This favorable environmental context supports Orexo’s sustainability efforts by reducing the carbon footprint associated with their operations.
Unlock 30+ emissions data points on Orexo
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Orexo
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
6.71%
...this company is doing 6.71% better in emissions than the industry average.
Founded in 1995 and headquartered in Uppsala, Sweden, Orexo operates within the industrial manufacturing sector, specializing in the development of pharmaceuticals with a focus on drug delivery technologies. The company’s primary market is the United States, where it commercializes Zubsolv® for the treatment of opioid dependence. Orexo’s portfolio extends to other therapeutic areas and products, with a strong commitment to innovation and addressing unmet medical needs.
emission intelligence's platform recommendations for Orexo
Orexo should undertake a thorough inventory of all Scope 1 emissions sources to identify and mitigate direct greenhouse gas emissions, potentially reducing their emissions by 15%.
Bad news, Orexo hasn't committed to SBTi climate goals yet
Orexo has not established specific commitments with the Science Based Targets initiative (SBTi) yet. This means the company has not publicly defined or committed to precise targets for reducing greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.